OncoMatch/Clinical Trials/NCT04519151
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Is NCT04519151 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Lenvatinib for ovarian neoplasms.
Treatment: Pembrolizumab · Lenvatinib — This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy — front-line
Have received a front-line platinum-based regimen per local standard of care or treatment guideline following the primary or interval debulking surgery with radiologically documented disease recurrence no earlier than 6 months following completion of platinum-based therapy.
Cannot have received: anti-PD-1 therapy
Exception: allowed if progression was documented over 6 months since completion of the immunotherapy maintenance treatment
Patients that received maintenance immune checkpoint inhibitors will be eligible if progression was documented over 6 months since completion of the immunotherapy maintenance treatment.
Cannot have received: lenvatinib (lenvatinib)
The participant has received prior lenvatinib.
Lab requirements
Blood counts
adequate organ function as defined by blood tests
Kidney function
adequate organ function as defined by blood tests
Liver function
adequate organ function as defined by blood tests
Have adequate organ function as defined by blood tests.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04519151 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, lenvatinib disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages